Compare TOST & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOST | DGX |
|---|---|---|
| Founded | 2012 | 1967 |
| Country | United States | United States |
| Employees | 6500 | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9B | 23.2B |
| IPO Year | 2021 | 1996 |
| Metric | TOST | DGX |
|---|---|---|
| Price | $34.74 | $238.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 13 |
| Target Price | $41.29 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 10.1M | 1.0M |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.82% |
| EPS Growth | ★ 1766.67 | 13.78 |
| EPS | 0.46 | ★ 5.08 |
| Revenue | $6,153,000,000.00 | ★ $11,035,000,000.00 |
| Revenue This Year | $22.69 | $7.53 |
| Revenue Next Year | $18.03 | $3.77 |
| P/E Ratio | $75.43 | ★ $46.95 |
| Revenue Growth | ★ 24.05 | 11.78 |
| 52 Week Low | $22.26 | $171.18 |
| 52 Week High | $45.64 | $240.13 |
| Indicator | TOST | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 71.98 | 74.55 |
| Support Level | $33.91 | $188.53 |
| Resistance Level | $37.08 | $240.13 |
| Average True Range (ATR) | 1.32 | 6.26 |
| MACD | 0.31 | 1.01 |
| Stochastic Oscillator | 79.81 | 95.48 |
Toast Inc is a cloud-based, all-in-one digital technology platform purpose-built for the restaurant community. The company provides a comprehensive platform of software-as-a-service (SaaS) products and financial technology solutions, including integrated payment processing, restaurant-grade hardware, and a broad ecosystem of third-party partners. It serves as a restaurant operating system, connecting front of house and back of house operations across service models such as dine-in, takeout, and delivery. It operates through one reportable segment consisting of its SaaS products, financial technology solutions, integrated payments, hardware, and partner ecosystem.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.